The New England Journal of Medicine Publishes Complete Data from ENRICH

The New England Journal of Medicine Publishes Complete Data from ENRICH, the First Positive Trial to Improve Functional and Economic Outcomes for Intracerebral Hemorrhage (ICH)

Nico Corporation, now part of Stryker, and a leader in minimally invasive parafascicular surgery (MIPS), has announced the publication of complete ENRICH (Early Minimally-invasive Removal of ICH) trial data in the New England Journal of Medicine. The trial showcased the efficacy of Nico's technology, BrainPath® and Myriad®, in treating intracerebral hemorrhage (ICH), the most deadly and disabling form of stroke.⁵

ENRICH met its primary endpoints showing MIPS improved outcomes for ICH patients with statistically significant improvement in utility-weighted modified Rankin Scale (UWmRS) at 180-days (0.458) versus MM (0.374), the difference showing a 98.1% posterior probability of superiority (95% CI, 0.005 to 0.163) and reduced mortality at 30-days (9.3%) compared to MM alone. Additionally, the MIPS approach decreased ICU length of stay (LOS) by 2.8 days and hospital LOS by 3.1 days.

The trial utilized Nico’s technological system solution, comprised of our patented technologies including the Nico BrainPath™ – the world’s first and only technology that achieves minimally-disruptive access using a trans sulcal and parafascicular surgical approach – and the Nico Myriad® that provides automated non-ablative tumor removal and hemorrhage evacuation.

Globally, 3.4 million people suffer hemorrhagic strokes (ICH) each year.¹ While ICH comprises up to 20 percent of all strokes that occur compared to ischemic stroke^,1 mortality and long-term disability are disproportionately higher among ICH patients.² In the United States, up to 50 percent will die within 30 days post-hemorrhage, and among survivors, only 25 percent will return to functional independence.² In addition to the human toll, hemorrhagic stroke costs the U.S. healthcare system approximately $17 billion, with $12 billion in estimated annual costs of care and productivity losses for survivors^.3 Overall, the trial showed early MIPS intervention for ICH led to improved functional outcomes.